Total Voting Rights and Block Listing Return

MaxCyte, Inc.

07 August 2023

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights and Block Listing Return

ROCKVILLE, Md., August 07, 2023 -- MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that as of 31 July 2023, the total issued stock capital of the Company was 103,504,571 shares of common stock, $0.01 par ("Common Stock") following further issue of new Common Stock in satisfaction of the exercise of share options. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

Block Listing Return

MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of applicant:		MaxCyte, Inc.
Name of scheme:		MaxCyte Long Term Incentive Plan
Period of return:	From:	1 October 2022	To:	31 July 2023
Balance of unallotted securities under scheme(s) from previous return:		11,529,603 ordinary shares of common stock at $0.01 each
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		1,600,258 ordinary shares of common stock at $0.01 each
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		9,929,345 ordinary shares of common stock at $0.01 each

Name of contact:	Douglas Swirsky, Chief Financial Officer
Telephone number of contact:	[phone]

For further information, please contact:

	MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
	Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
	UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

 

END